MARPLAN Drug Patent Profile

Which patents cover Marplan, and when can generic versions of Marplan launch?

Marplan is a drug marketed by Lifsa Drugs and is included in one NDA.

The generic ingredient in MARPLAN is isocarboxazid. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the isocarboxazid profile page.

Summary for MARPLAN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	65
Patent Applications:	5,776
Drug Prices:	Drug price information for MARPLAN
What excipients (inactive ingredients) are in MARPLAN?	MARPLAN excipients list
DailyMed Link:	MARPLAN at DailyMed

See drug prices for MARPLAN

Pharmacology for MARPLAN

Drug Class	Monoamine Oxidase Inhibitor
Mechanism of Action	Monoamine Oxidase Inhibitors

US Patents and Regulatory Information for MARPLAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lifsa Drugs	MARPLAN	isocarboxazid	TABLET;ORAL	011961-001	Approved Prior to Jan 1, 1982		RX	Yes	Yes

MARPLAN (isocarboxazid) market dynamics and financial trajectory: exclusivity, pricing pressure, and competitive risks

Last updated: July 30, 2026

MARPLAN (isocarboxazid) is an older, off-patent antidepressant with limited brand-driven financial upside. Market dynamics are dominated by: generic availability and clinician switching, episodic supply constraints typical of legacy sterile manufacturing, payor-driven price compression, and uneven demand tied to MAOI prescribing patterns. The financial trajectory is defined less by IP timelines and more by retail reimbursement, wholesaler stocking behavior, and the availability of alternative MAOIs.

What is MARPLAN and how does it fit in the MAOI antidepressant market?

MARPLAN is an oral antidepressant in the monoamine oxidase inhibitor (MAOI) class (active ingredient: isocarboxazid). Its market position is shaped by two realities: MAOIs are used less often than SSRIs/SNRIs and are more protocol-sensitive (dietary and drug-interaction management). As a result, MARPLAN demand is smaller and more fragmented than modern antidepressants, with prescription volume concentrated among experienced prescribers, specific intolerance profiles, or treatment-resistant cases where MAOIs are considered.

How large is the demand pool relative to modern antidepressants?

MARPLAN competes within a niche of antidepressants where prescribers still use MAOIs. The practical benchmark for market sizing is not “antidepressant share,” but MAOI share and “market stability” versus competitors in the same class:

• Other oral MAOIs (brand and generic)
• Transdermal or reversible alternatives used for MAOI-like symptom profiles (where applicable)
• Non-MAOI antidepressants with better interaction profiles that dominate prescribing

Where does MARPLAN sell: retail vs specialty channels?

MARPLAN is typically distributed through standard wholesaler and retail pharmacy channels rather than specialty channels. That channel structure increases sensitivity to:

• Wholesale acquisition cost (WAC) changes
• Pharmacy benefit manager (PBM) contracting and formulary design
• Stocking risk when product availability tightens

What has driven MARPLAN’s market dynamics over the past decade?

MARPLAN’s dynamics track the behavior of legacy branded generics and off-patent products:

1. Generic substitution has been structurally available for isocarboxazid.
2. Formulary pressure has reduced premium pricing durability.
3. Prescriber behavior matters more than marketing, since use is protocol-dependent.
4. Supply and quality events have outsized impact because the MAOI niche cannot easily absorb prolonged stock-outs.

Is MARPLAN “priced like a niche brand” or “priced like a legacy generic”?

In off-patent antidepressants, brand economics typically drift toward generic-parity pricing unless there is differentiation via availability, package configuration, or persistent insurer coverage of the brand. For MARPLAN, market dynamics usually reflect:

• Lower payer willingness to reimburse premium pricing versus generics
• Pharmacy procurement behavior that favors lowest-cost stocked alternatives
• Periodic re-stabilization when supply disruptions raise effective access constraints

How does the competitive landscape affect MARPLAN revenue and volume?

MARPLAN competes against:

• Generic isocarboxazid products (direct substitution)
• Other MAOIs (class substitution)
• Non-MAOI antidepressants (clinical substitution driven by interaction profile and monitoring burden)

What competitive factors most influence net sales?

The most financially relevant levers for MARPLAN are not differentiated efficacy or novel delivery, but:

• Net price after PBM rebates and discounts
• Access through formularies and prior authorization practices (if any)
• Availability and lot-level stability (stock-outs cause irreversible switching)
• Prescriber familiarity and continuity when generics change appearance, sourcing, or packaging

Generic and brand mix: what does it mean for financial trajectory?

For off-patent products, revenue generally splits into:

• Residual brand demand due to inertia, prescriber preference, or pharmacy switching friction
• A larger volume base on generics, which caps price and, by extension, caps brand revenue if brand premium is not maintained

What is the financial trajectory for MARPLAN: stable, declining, or episodic?

MARPLAN’s financial trajectory is best characterized as declining or flat with episodic volatility driven by channel and access events rather than long-run growth.

Why is long-term growth structurally limited?

MARPLAN faces structural growth constraints:

• Off-patent status and generic competition for isocarboxazid
• Niche prescribing behavior for MAOIs
• Lack of differentiation that can support sustained market expansion
• High payer sensitivity to low-margin generics in chronic antidepressant categories

What events create near-term revenue spikes or dips?

Near-term movement is typically caused by:

• Supply constraints or manufacturing interruptions that temporarily reduce generic availability
• PBM/insurer formulary changes that alter preferred status
• Package NDC changes or label updates that affect pharmacy automation and ordering behavior
• Wholesale channel destocking or restocking cycles

When does MARPLAN lose exclusivity or face IP-driven market shifts?

MARPLAN is not supported by a typical, modern brand exclusivity profile that governs long-horizon financial trajectory. Market changes are instead tied to:

• the absence of meaningful brand patent protection (functional off-patent reality)
• the resulting dominance of generic supply and pricing dynamics

How does Orange Book status typically affect MARPLAN’s commercialization?

For legacy small-molecule antidepressants, the Orange Book often shows limited or expired protections. That translates into:

• low leverage for delayed generic entry
• routine Paragraph IV incentives being muted when multiple competitors and generics already exist

(If MARPLAN has any active Orange Book listed patents, their impact is generally outweighed by off-patent market access dynamics for isocarboxazid.)

What patents protect MARPLAN and what is the strength of the patent estate?

A modern “patent estate” analysis for MARPLAN should be approached as an off-patent brand review. Financially, the key point is that isocarboxazid tablets generally do not carry an active blocking portfolio that can sustain premium pricing or delay generic competition.

What IP categories matter for an off-patent MAOI?

Even when main composition-of-matter protections are expired, residual IP can exist in niche forms:

• method-of-use claims for specific dosing regimens or patient subsets
• formulation or stability claims tied to manufacturing conditions
• packaging or process claims

For MARPLAN’s market economics, the presence or absence of enforceable claims matters less than whether they can practically block generic launch.

What is the FDA regulatory status of MARPLAN and how does it affect market access?

MARPLAN is FDA-approved as an oral antidepressant. Regulatory status affects:

• which products can be substituted under pharmacy switching rules
• labeling-driven prescriber confidence and safety protocol adherence
• product availability and compliance with current good manufacturing practice (cGMP)

What FDA pathway risks exist for entrants?

For off-patent small molecules, generic competitors typically use Abbreviated New Drug Application (ANDA) pathways once reference-listed status supports it. The financial effect is direct:

• increased supply
• price compression
• reduced brand share

How do market dynamics differ between MARPLAN’s dosage forms?

MARPLAN is marketed as oral tablets. For legacy oral products, key financial factors include:

• tablet strength distribution (demand mix across strengths)
• manufacturing line efficiency and cost
• stability and shelf-life management (drives supply continuity and wholesaler confidence)

Because the delivery system is not innovative, dosage-form-level differentiation does not typically sustain premium brand economics against generics.

What generic entry risks exist for MARPLAN?

Generic entry risk is low as an “entry” event because generic isocarboxazid products have already established market presence. The more relevant risk is:

• additional market-share gains by low-cost suppliers
• episodic availability shifts that re-price the effective market

How do supply constraints change the effective competitive set?

If specific generic suppliers face shortages, MARPLAN brand sales can rise briefly. That upside is transient because:

• wholesalers revert to preferred low-cost sources once availability improves
• prescribers often refill long-term MAOI therapy from whatever is stocked

Which companies sell competing MAOIs and how does that affect MARPLAN?

MARPLAN’s competitive landscape is primarily generic-focused. The financially material competitors are:

• generic isocarboxazid manufacturers across NDCs and strengths
• other MAOI brands/generics that compete for the same niche patients

In MAOI markets, the number of active suppliers at any time can be more important than brand-level market share. A market with fewer functioning suppliers will show higher volatility in pricing and brand capture during shortages.

How does MARPLAN compare with other MAOIs on market structure and pricing?

Compared with alternatives:

• MAOIs with fewer generic competitors can maintain slightly higher effective pricing.
• MAOIs that have better continuity of supply exhibit higher channel confidence.
• MAOIs with more interaction-friendly use patterns (or better managed safety protocols via modern clinical practice) can win share even within the same class.

For MARPLAN, the key comparison is against generics of isocarboxazid and class peers rather than against new antidepressants.

What litigation or settlement activity could affect MARPLAN’s financials?

For legacy small molecules with extensive generic competition, Paragraph IV-driven litigation is less often a major financial driver than:

• market access through generic supply expansion
• distribution and pricing contracts
• supply and manufacturing qualification events

As a result, litigation risk is not typically the main determinant of MARPLAN’s trajectory, absent a documented active dispute that blocks new ANDAs or changes pricing/market access.

What is the likely revenue exposure and what drives net sales?

MARPLAN revenue exposure is driven by:

• unit demand stability in a niche antidepressant category
• net price after discounts
• channel share versus generics (brand capture)

Net sales are usually sensitive to:

• PBM formulary status and contract terms
• pharmacy wholesaler purchasing preference
• the relative landed cost of stocked generics

Revenue mechanics for legacy branded generics

Typical pattern in this category:

• brand revenue declines as generic share increases
• brand share can stabilize when prescribers remain loyal or when supply disruptions limit generic substitution
• net price compression reduces upside during any unit growth

Key indicators to track for MARPLAN financial trajectory

Operational indicators often predict financial movement faster than demand indicators:

• wholesaler inventory levels and backorder rates for MARPLAN and generic isocarboxazid
• WAC and net price changes tied to PBM contracting cycles
• NDC-level availability and lot release consistency
• pharmacy claims trends and switching behavior at the NDC level

Key Takeaways

• MARPLAN is an off-patent, niche MAOI where financial trajectory is dominated by generic substitution, formulary and PBM pressure, and supply continuity rather than long-horizon IP events.
• Market dynamics are episodic: stock-outs or supply disruptions can temporarily shift demand, but generic availability typically restores price compression.
• Revenue exposure is primarily net price (rebates and discounts) and brand share versus generic isocarboxazid suppliers, not premium clinical positioning.
• Litigation and exclusivity timelines are usually not the primary drivers for a legacy MAOI’s market outcomes; access and channel economics matter more.

FAQs

1. Why do MAOI prescriptions shift between brands and generics so quickly?
   Because prescribers often rely on whatever is stocked and reimbursed, and dosing protocols are standardized, making NDC-level substitution easy when supply is stable.

2. How do PBM formulary changes typically impact legacy antidepressant brands like MARPLAN?
   They usually drive net price compression and reduce brand preference, accelerating share loss to the lowest-cost stocked generic.

3. What supply issues most affect MARPLAN market share?
   Manufacturing interruptions or slow lot releases that create backorders for either MARPLAN or key generic sources, which can permanently shift dispensing patterns.

4. Do MAOI interaction protocols increase payer scrutiny or utilization management?
   They can, because MAOI use requires more management. That affects authorization behavior and can reduce maintenance prescribing when monitoring capacity is limited.

5. Can MARPLAN gain share during generic shortages, and how durable is that gain?
   It can temporarily increase demand when generics are unavailable, but gains are generally not durable once the generic supply base normalizes and PBM incentives favor the lowest-cost options.

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-07-30).
2. U.S. Food and Drug Administration. Drugs@FDA: MARPLAN. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm (accessed 2026-07-30).